These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29904742)

  • 21. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
    Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disparities in the Local Management of Breast Cancer in the US according to Health Insurance Status.
    Churilla TM; Egleston B; Bleicher R; Dong Y; Meyer J; Anderson P
    Breast J; 2017 Mar; 23(2):169-176. PubMed ID: 27797159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA: Declining utilization of prostate brachytherapy.
    Andring L; Yoder A; Pezzi T; Tang C; Kumar R; Mahmood U; Walker GV
    Brachytherapy; 2022; 21(1):6-11. PubMed ID: 34420862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in Treatment for Prostate Cancer in China: Preliminary Patterns of Care Study in a Single Institution.
    Zhao F; Shen J; Yuan Z; Yu X; Jiang P; Zhong B; Xiang J; Ren G; Xie L; Yan S
    J Cancer; 2018; 9(10):1797-1803. PubMed ID: 29805706
    [No Abstract]   [Full Text] [Related]  

  • 25. Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands.
    Evers J; Kerkmeijer LGW; van den Bergh RCN; van der Sangen MJC; Hulshof MCCM; Bloemers MCWM; Siesling S; Aarts MJ; Aben KKH; Struikmans H
    Radiother Oncol; 2022 Dec; 177():134-142. PubMed ID: 36328090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of State-Level Medicaid Expansion With Treatment of Patients With Higher-Risk Prostate Cancer.
    Liu W; Goodman M; Filson CP
    JAMA Netw Open; 2020 Oct; 3(10):e2015198. PubMed ID: 33026448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
    Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
    Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.
    Mahal AR; Mahal BA; Nguyen PL; Yu JB
    Cancer; 2018 Feb; 124(4):752-759. PubMed ID: 29084350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disparities in the management and outcome of cervical cancer in the United States according to health insurance status.
    Churilla T; Egleston B; Dong Y; Shaikh T; Murphy C; Mantia-Smaldone G; Chu C; Rubin S; Anderson P
    Gynecol Oncol; 2016 Jun; 141(3):516-523. PubMed ID: 27012428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Yang DD; Mahal BA; Muralidhar V; Boldbaatar N; Labe SA; Nezolosky MD; Vastola ME; Beard CJ; Martin NE; Mouw KW; Orio PF; King MT; Nguyen PL
    Cancer; 2017 Dec; 123(24):4832-4840. PubMed ID: 28832984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    Huang H; Muscatelli S; Naslund M; Badiyan SN; Kaiser A; Siddiqui MM
    J Urol; 2019 Jan; 201(1):120-128. PubMed ID: 30059685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology.
    Gerhard RS; Patil D; Liu Y; Ogan K; Alemozaffar M; Jani AB; Kucuk ON; Master VA; Gillespie TW; Filson CP
    Urol Oncol; 2017 May; 35(5):250-256. PubMed ID: 28089387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients With Prostate Cancer.
    Fossati N; Nguyen DP; Trinh QD; Sammon J; Sood A; Larcher A; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1351-8. PubMed ID: 26553765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate.
    Dess RT; Suresh K; Zelefsky MJ; Freedland SJ; Mahal BA; Cooperberg MR; Davis BJ; Horwitz EM; Terris MK; Amling CL; Aronson WJ; Kane CJ; Jackson WC; Hearn JWD; Deville C; DeWeese TL; Greco S; McNutt TR; Song DY; Sun Y; Mehra R; Kaffenberger SD; Morgan TM; Nguyen PL; Feng FY; Sharma V; Tran PT; Stish BJ; Pisansky TM; Zaorsky NG; Moraes FY; Berlin A; Finelli A; Fossati N; Gandaglia G; Briganti A; Carroll PR; Karnes RJ; Kattan MW; Schipper MJ; Spratt DE
    JAMA Oncol; 2020 Dec; 6(12):1912-1920. PubMed ID: 33090219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy.
    Grant SR; Walker GV; Koshy M; Shaitelman SF; Klopp AH; Frank SJ; Pugh TJ; Allen PK; Mahmood U
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):968-75. PubMed ID: 26452570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate.
    Harlan L; Brawley O; Pommerenke F; Wali P; Kramer B
    J Clin Oncol; 1995 Jan; 13(1):93-100. PubMed ID: 7799048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is primary prostate cancer treatment influenced by likelihood of extraprostatic disease? A surveillance, epidemiology and end results patterns of care study.
    Holmes JA; Wang AZ; Hoffman KE; Hendrix LH; Rosenman JG; Carpenter WR; Godley PA; Chen RC
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):88-94. PubMed ID: 22300560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    JAMA Oncol; 2015 Jun; 1(3):334-40. PubMed ID: 26181182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Irradiation of localized prostate cancer in the elderly: A systematic literature review.
    Marotte D; Chand-Fouche ME; Boulahssass R; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():1-8. PubMed ID: 35492872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.